
Strengthening the customer experience one provider at a time
SkinPen Creates the Results. Glacial Skin Elevates the Experience.
A partnership with Crown Aesthetics | Glacial Skin | Confidential
SkinPen delivers consistent collagen induction with a manageable recovery profile. But in a market where patients increasingly expect premium, zero-downtime experiences, there's an opportunity to differentiate.
What patients perceive after microneedling — even when clinical outcomes are excellent:
Social downtime; reluctance to schedule before events
Anxiety about "doing something wrong" during recovery
Perceived severity exceeds clinical reality
Uncertainty about post-care routine
For Fitzpatrick IV–VI patients, post-procedure inflammation carries additional risk of hyperpigmentation — a barrier to expanding SkinPen's diverse patient base.

During treatment: SkinPen needles create controlled micro-channels in the dermis.
Minutes to hours: Platelet activation triggers growth factor release; neutrophils arrive.
Hours to days: Growth factors recruit fibroblasts to the wound site.
Weeks to months: New collagen III forms, then converts to collagen I over time.
Micro-channels begin closing within minutes of needle withdrawal — the mechanical stimulus is already delivered.
Growth factor release is immediate and irreversible upon platelet activation.
Fibroblast recruitment occurs over hours to days.
Collagen remodeling unfolds over 3–6 months — a 10-minute cryomodulation session addresses only the acute inflammatory surface response.
Decrease in post-procedure pain scores
Reported improved recovery experience
Faster resolution of visible redness






*Glacial® Rx is FDA-cleared for temporary reduction of pain and inflammation


Our Patented Cryomodulation™ stops the inflammatory cascade that causes redness, eliminating downtime.
This calming effect creates the perfect cellular environment for serum absorption, while vasoconstriction 'locks in' the treatment for a superior, longer-lasting glow.
Safe for all skin types and all seasons, broadening patient accessibility.
Harvard-developed, FDA-cleared*, establishing a unique and credible category.
Fast training and seamless fit into any existing practice workflow.
Treats multiple conditions with one system, maximizing ROI.
*Glacial® Rx is FDA-cleared for temporary reduction of pain and inflammation




→ More sessions per patient
→ Higher revenue per session
→ More SkinPen candidates (including Fitzpatrick IV–VI)
Patients reported they would repeat and recommend Glacial® Skin treatment
Patients reported brighter, rejuvenated, or more even skin tone at one month
Patients showed visible improvement according to physician assessment
Visible calming of redness and inflammation right after treatment
Results continue to improve for up to 3 months post-treatment
Safe for all Fitzpatrick skin types (I-VI) with zero serious adverse events
Patients can immediately resume normal activities and even book same day or the day before events without risk of redness giving them that perfect Glacial glow.
Even sensitive, rosacea-prone skin shows significant reductions in post-treatment redness. The Skin pen protocol calms even the most reactive skin types, making the treatment accessible to patients who previously avoided skin treatments due to sensitivity concerns.
The melanin-normalizing effect enhances Skin Pen's brightening power. Patients with uneven tone or melasma see exceptional brightness and evenness, creating a luminous, porcelain-smooth appearance that photographs beautifully.
Neck and decollete are among the fastest-growing treatment areas in aesthetic medicine — and among the most sensitive. Thinner skin means more visible erythema and greater patient concern about post-procedure appearance.
10 standalone Glacial Skin treatments per week × $200 average = $2,000/week = $104,000/year
20 standalone treatments per week × $225 average = $4,500/week = $234,000/year
30 standalone treatments per week × $250 average = $7,500/week = $390,000/year
Glacial gives providers a post-treatment protocol they can stand behind. More confidence means providers use more aggressive settings, treat a broader patient base, and recommend more sessions.
Better clinical outcomes combined with a premium recovery experience drives higher patient satisfaction. Higher satisfaction means more referrals and stronger reviews.
More patients per provider means more cartridge consumption, more recurring Crown revenue, and a stronger argument for SkinPen over competing platforms.
Creates the micro-channels — delivering controlled collagen induction
Calms the acute inflammatory response and optimizes the skin barrier
Living biome colonizes an optimized, calm skin environment
This three-step protocol is exclusive to Crown's ecosystem. No competitor can replicate it — because no competitor has all three components. It positions Crown not as a device company, but as a complete skin health platform.
Glacial Skin is a platform-wide enhancement for Crown's entire installed base — not a single-device add-on.
"100% of clinical trial participants reported they would repeat the cryomodulation experience or recommend it to others." — Clinical trial patient satisfaction data
"The post-procedure experience transformed how patients talked about their treatment — they focused on how they felt leaving, not the discomfort during." — Provider feedback, clinical adoption program
Research in behavioral psychology shows that people judge experiences primarily by two moments: the peak (most intense point) and the end (how it concludes). This is the Peak-End Rule.
Microneedling's peak is the discomfort during treatment. Glacial Skin replaces the ending — transforming it from "lingering redness and warmth" to "cool, calm, glowing skin."
Relaxation — Patients experience a soothing, clinical cool-down
Visible improvement — Immediate reduction in redness creates a tangible "I can see the difference" moment
Positive memory formation — The treatment ends on a high note, reshaping how patients remember the entire session
Wellness finish — The clinical treatment concludes with a sense of care, not just procedure completion
Q1: Does cooling reduce SkinPen's collagen induction results?
No. The collagen cascade is initiated at the subcellular level the moment SkinPen's needles create micro-channels. Growth factor release is immediate and irreversible upon platelet activation. Surface cryomodulation addresses the acute inflammatory response (redness, swelling, discomfort) without interfering with the deeper wound-healing process that drives collagen remodeling over 3–6 months.
Q2: Is Glacial Skin FDA-cleared for post-microneedling use?
Glacial Rx is FDA cleared for reduction of pain and inflammation (erythema, edema). Micro needling triggers the same effects (erythema, edema, pain) addressed by these clearances. The device holds a unique FDA product code — no other cryomodulation device is in its class.
Q3: How does this integrate into existing SkinPen workflows?
Glacial Skin is applied immediately after the SkinPen treatment is complete, as the final step in the procedure. No room reconfiguration, no complex training. The session adds approximately 10 minutes. Providers can begin offering it the same week they receive the device.
Q4: What about patients with topical sensitivities or unexpected reactions?
This is one of Glacial Skin's strongest value propositions for SkinPen practices. Post-microneedling skin is more permeable and reactive. Cryomodulation calms the skin, reducing irritation, inflammation, and unwanted skin reactions. It is a safety net that elevates the standard of care.
Q5: Does this compete with SkinPen's messaging?
Glacial Skin complements SkinPen's value proposition — it does not compete with it. SkinPen delivers the collagen induction. Glacial Skin manages the recovery experience. The messaging is additive: "SkinPen results, now with a premium recovery experience."
SkinPen has built the gold standard in microneedling. Glacial Skin is here to protect that standard — by giving providers a clinically validated post-treatment protocol that improves the patient experience, expands the addressable market, and differentiates Crown's entire ecosystem.
This is not about adding another device. It is about adding a layer of clinical excellence to everything Crown already does well.
Let's explore what this could look like.
A Strategic Adjunct to Enhance the SkinPen Experience